Mandate

Vinge advises Cellink in conjunction with the acquisition of cytena

August 05, 2019 M&A

Vinge has advised Cellink AB (publ) in connection with the acquisition of all shares in cytena GmbH. cytena is a life science company which focuses on single cell technologies.

Cytena was established in 2014 from the Institute for Microsystems Technology at the University of Freiburg and primarily sells solutions for the handling of biological cells. The purchase price amounts to MEUR 30.25, corresponding to MSEK 323, and is paid with 1/3 in cash and 2/3 in newly issued Cellink shares. Cellink will convene an extraordinary general meeting which will resolve upon the directed issue of shares to the sellers of cytena.

Vinge’s team primarily consisted of Anders Strid, Daniel Lennartsson Anderås, Alexander Lindeberg and Adam Loewenstein.

Related

Vinge advises on the sale of Wais to Sertion

Vinge has advised the sellers in connection with the sale of Wais AB to Sertion AB. Wais conducts operations relating to boiler service and maintenance, flue gas cleaning, mechanical works and fan service for, among others, combined heat and power plants.
May 19, 2025

Vinge advises SBB in connection with its acquisition of shares in PPI against payment through a share issue in-kind

Vinge has advised SBB in connection with the agreement entered into with TRG, a Norwegian group of companies controlled by Kjell Inge Røkke and the principal owner of Aker ASA. Under the agreement, SBB has undertaken to carry out a share issue in-kind to TRG or, as applicable, Aker Property Group.
May 16, 2025

Vinge has advised Stendörren Fastigheter in connection with a directed share issue of approximately SEK 300 million

Vinge has advised the property company Stendörren Fastigheter AB (publ) in connection with a directed share issue through which the company raises proceeds of approximately SEK 300 million before transaction costs.
May 14, 2025